Avacta Appoints Patrick Vink Deputy Chairman
Avacta Group PLC announced the appointment of Patrick Vink as Deputy Chairman of the Board of Directors, bringing extensive experience in pharmaceutical partnering, financing, and operations. Vink's background includes executive roles at Cubist Pharmaceuticals, where he managed global operations and P&L prior to its acquisition by Merck, and previous positions at Sanofi, Biogen, Sandoz, and Mylan. He currently serves on the boards of Arch Biopartners Inc. and Spero Therapeutics Inc., and chairs several private companies, indicating a strong network and deep industry knowledge that could support Avacta's pipeline advancement and partnership discussions, particularly as the company anticipates upcoming data from its pre|CISION® platform, including initial clinical results for AVA6103.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| LONDON and PHILADELPHIA - July 8, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre | CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. |
- Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. He is also Chairman of three privately held companies, Micreos Group (Bilthoven, Netherlands), Secura Bio Inc. (Boston, USA), and F2G Ltd (Manchester, UK), and is a senior advisor to Athyrium Capital Management LP (New York, USA) and Forbion Ventures (Naarden, Netherlands).
Christina Coughlin, CEO of Avacta commented:
| "We are delighted to welcome Patrick to the Board of Directors of Avacta. His appointment adds considerable sector experience in Pharma partnering, financing, andoperations, having worked for a number of European and US companies, both private and listed. His extensive experience and expertise in building companies comes at a key time for Avacta as we advance our pipeline, based on our proprietary pre | CISION® platform which brings unique potential advantages to cancer patients, and continue constructive partnership discussions across our asset portfolio." |
| Patrick Vink, Deputy Chairman of Avacta, added: | |
| "I am excited to join the Board of Avacta at this important time for the company. Avacta's pre | CISION® technology has the potential to change the way that the field thinks about cancer therapy. Upcoming data, including the first clinical results from the Gen Two product AVA6103, could be transformative for Avacta, and I look forward to working with management and my fellow Directors to lead the company on the journey ahead." |
Previously, Dr. Vink served as Executive Vice-President and Chief Operating Officer at Cubist Pharmaceuticals Inc., a leader in the anti-infective and acute care hospital market. He oversaw all worldwide commercial and technical operations as well as managing the company's P&L until the successful acquisition of Cubist by Merck. He joined Cubist in 2012 as Senior Vice President and Head of International Business Operations having started his career at Sanofi and held senior executive roles at Biogen, Sandoz, and Mylan.
- Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1992 at the University of Rochester.
About FAP-Exd (AVA6103)
Mr Vink, aged 63, currently holds or has held the following directorships or partnerships in the past five years:
| Current Directorships/Partnerships | Past Directorships/Partnerships within the last five years |
| Spero Therapeutics Inc. | Essential Pharma Limited |
| Spero Europe Limited | SQZ Biotechnologies Co |
| F2G Ltd | BiognoSYS AG |
| Micreos BV | Santhera Pharmaceuticals Holding AG |
| Secura Bio Inc | Amryt Pharma Plc |
| Arch Biopartners Inc. | NMD Pharma A/S |
Athyrium Capital Management LP
Forbion Ventures
Vink Advisory Services
Mr Vink currently holds no ordinary shares in the Company. There are no further disclosures required in accordance with AIM Rule 17 or Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Mr Vink.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.